Proactiveinvestors Australia MaxCyte Inc https://www.proactiveinvestors.com.au Proactiveinvestors Australia MaxCyte Inc RSS feed en Wed, 20 Jan 2021 10:39:54 +1100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) MaxCyte inks licensing deal with Myeloid Therapeutics to advance cancer therapies https://www.proactiveinvestors.com.au/companies/news/938033/maxcyte-inks-licensing-deal-with-myeloid-therapeutics-to-advance-cancer-therapies-938033.html Mon, 11 Jan 2021 07:50:00 +1100 https://www.proactiveinvestors.com.au/companies/news/938033/maxcyte-inks-licensing-deal-with-myeloid-therapeutics-to-advance-cancer-therapies-938033.html MaxCyte commercial arm trading ahead of expectations; working on strategy for and future funding of the CARMA business https://www.proactiveinvestors.com.au/companies/news/937265/maxcyte-commercial-arm-trading-ahead-of-expectations-working-on-strategy-for-and-future-funding-of-the-carma-business-937265.html Wed, 23 Dec 2020 07:54:00 +1100 https://www.proactiveinvestors.com.au/companies/news/937265/maxcyte-commercial-arm-trading-ahead-of-expectations-working-on-strategy-for-and-future-funding-of-the-carma-business-937265.html Maxcyte: At the forefront of cell therapy revolution https://www.proactiveinvestors.com.au/companies/news/214111/maxcyte-at-the-forefront-of-cell-therapy-revolution-214111.html Fri, 13 Nov 2020 15:31:00 +1100 https://www.proactiveinvestors.com.au/companies/news/214111/maxcyte-at-the-forefront-of-cell-therapy-revolution-214111.html MaxCyte subsidiary CARMA to present MCY-M11 candidate data at meeting of Society for Immunotherapy of Cancer https://www.proactiveinvestors.com.au/companies/news/933475/maxcyte-subsidiary-carma-to-present-mcy-m11-candidate-data-at-meeting-of-society-for-immunotherapy-of-cancer-933475.html Mon, 09 Nov 2020 14:07:00 +1100 https://www.proactiveinvestors.com.au/companies/news/933475/maxcyte-subsidiary-carma-to-present-mcy-m11-candidate-data-at-meeting-of-society-for-immunotherapy-of-cancer-933475.html Growing MaxCyte bolsters leadership team with three senior appointments https://www.proactiveinvestors.com.au/companies/news/931266/growing-maxcyte-bolsters-leadership-team-with-three-senior-appointments-931266.html Tue, 13 Oct 2020 06:26:00 +1100 https://www.proactiveinvestors.com.au/companies/news/931266/growing-maxcyte-bolsters-leadership-team-with-three-senior-appointments-931266.html MaxCyte report 'extraordinary first half' with revenue 30% higher than same period last year https://www.proactiveinvestors.com.au/companies/news/930448/maxcyte-report--extraordinary-first-half--with-revenue-30-higher-than-same-period-last-year-930448.html Thu, 01 Oct 2020 07:23:00 +1000 https://www.proactiveinvestors.com.au/companies/news/930448/maxcyte-report--extraordinary-first-half--with-revenue-30-higher-than-same-period-last-year-930448.html Maxcyte lifts full-year revenue guidance https://www.proactiveinvestors.com.au/companies/news/929506/maxcyte-lifts-full-year-revenue-guidance-929506.html Mon, 21 Sep 2020 06:47:00 +1000 https://www.proactiveinvestors.com.au/companies/news/929506/maxcyte-lifts-full-year-revenue-guidance-929506.html MaxCyte appoints former healthcare analyst Amanda Murphy as its chief financial officer https://www.proactiveinvestors.com.au/companies/news/928611/maxcyte-appoints-former-healthcare-analyst-amanda-murphy-as-its-chief-financial-officer-928611.html Wed, 09 Sep 2020 06:42:00 +1000 https://www.proactiveinvestors.com.au/companies/news/928611/maxcyte-appoints-former-healthcare-analyst-amanda-murphy-as-its-chief-financial-officer-928611.html MaxCyte expands phase I cancer trial to two further centres https://www.proactiveinvestors.com.au/companies/news/926887/maxcyte-expands-phase-i-cancer-trial-to-two-further-centres-926887.html Tue, 18 Aug 2020 12:11:00 +1000 https://www.proactiveinvestors.com.au/companies/news/926887/maxcyte-expands-phase-i-cancer-trial-to-two-further-centres-926887.html MaxCyte Inc: Analyst talks expansion of its phase I clinical trial of MCY-M11 https://www.proactiveinvestors.com.au/companies/news/926934/maxcyte-inc-analyst-talks-expansion-of-its-phase-i-clinical-trial-of-mcy-m11-926934.html Tue, 18 Aug 2020 11:48:00 +1000 https://www.proactiveinvestors.com.au/companies/news/926934/maxcyte-inc-analyst-talks-expansion-of-its-phase-i-clinical-trial-of-mcy-m11-926934.html MaxCyte: Expanded prospects for CARMA https://www.proactiveinvestors.com.au/companies/news/926922/maxcyte-expanded-prospects-for-carma-926922.html Tue, 18 Aug 2020 09:27:00 +1000 https://www.proactiveinvestors.com.au/companies/news/926922/maxcyte-expanded-prospects-for-carma-926922.html MaxCyte Inc 'demonstrating outstanding progress' as first half revenues climb 30% https://www.proactiveinvestors.com.au/companies/news/924260/maxcyte-inc--demonstrating-outstanding-progress--as-first-half-revenues-climb-30-924260.html Wed, 15 Jul 2020 10:43:00 +1000 https://www.proactiveinvestors.com.au/companies/news/924260/maxcyte-inc--demonstrating-outstanding-progress--as-first-half-revenues-climb-30-924260.html MaxCyte: Firing on all cylinders https://www.proactiveinvestors.com.au/companies/news/924256/maxcyte-firing-on-all-cylinders-924256.html Wed, 15 Jul 2020 10:35:00 +1000 https://www.proactiveinvestors.com.au/companies/news/924256/maxcyte-firing-on-all-cylinders-924256.html MaxCyte performs strongly in H1; CARMA Cell Therapies expected to be self-funding by year-end https://www.proactiveinvestors.com.au/companies/news/924235/maxcyte-performs-strongly-in-h1-carma-cell-therapies-expected-to-be-self-funding-by-year-end-924235.html Wed, 15 Jul 2020 08:55:00 +1000 https://www.proactiveinvestors.com.au/companies/news/924235/maxcyte-performs-strongly-in-h1-carma-cell-therapies-expected-to-be-self-funding-by-year-end-924235.html MaxCyte Inc - Proactive One2One Virtual Event https://www.proactiveinvestors.com.au/companies/news/923916/maxcyte-inc---proactive-one2one-virtual-event-923916.html Fri, 10 Jul 2020 06:41:00 +1000 https://www.proactiveinvestors.com.au/companies/news/923916/maxcyte-inc---proactive-one2one-virtual-event-923916.html MaxCyte: A win in gene silencing with APEIRON Biologics https://www.proactiveinvestors.com.au/companies/news/923702/maxcyte-a-win-in-gene-silencing-with-apeiron-biologics-923702.html Wed, 08 Jul 2020 10:19:00 +1000 https://www.proactiveinvestors.com.au/companies/news/923702/maxcyte-a-win-in-gene-silencing-with-apeiron-biologics-923702.html Maxcyte deal with APEIRON Biologics 'highlights value of its Flow Electroporation technology' https://www.proactiveinvestors.com.au/companies/news/923711/maxcyte-deal-with-apeiron-biologics--highlights-value-of-its-flow-electroporation-technology--923711.html Wed, 08 Jul 2020 09:49:00 +1000 https://www.proactiveinvestors.com.au/companies/news/923711/maxcyte-deal-with-apeiron-biologics--highlights-value-of-its-flow-electroporation-technology--923711.html MaxCyte signs clinical and commercial licensing deal APEIRON Biologics https://www.proactiveinvestors.com.au/companies/news/923676/maxcyte-signs-clinical-and-commercial-licensing-deal-apeiron-biologics-923676.html Wed, 08 Jul 2020 06:26:00 +1000 https://www.proactiveinvestors.com.au/companies/news/923676/maxcyte-signs-clinical-and-commercial-licensing-deal-apeiron-biologics-923676.html Maxcyte to present clinical data from MCY-M11 phase one trial at American Society of Clinical Oncology https://www.proactiveinvestors.com.au/companies/news/919559/maxcyte-to-present-clinical-data-from-mcy-m11-phase-one-trial-at-american-society-of-clinical-oncology-919559.html Thu, 14 May 2020 07:29:00 +1000 https://www.proactiveinvestors.com.au/companies/news/919559/maxcyte-to-present-clinical-data-from-mcy-m11-phase-one-trial-at-american-society-of-clinical-oncology-919559.html MaxCyte deal with Caribou 'demonstrates expertise and value' of its Flow Electroporation technology https://www.proactiveinvestors.com.au/companies/news/919265/maxcyte-deal-with-caribou--demonstrates-expertise-and-value--of-its-flow-electroporation-technology-919265.html Mon, 11 May 2020 12:10:00 +1000 https://www.proactiveinvestors.com.au/companies/news/919265/maxcyte-deal-with-caribou--demonstrates-expertise-and-value--of-its-flow-electroporation-technology-919265.html MaxCyte: Gold standard technology draws CRISPR pioneer Caribou https://www.proactiveinvestors.com.au/companies/news/919118/maxcyte-gold-standard-technology-draws-crispr-pioneer-caribou-919118.html Thu, 07 May 2020 14:30:00 +1000 https://www.proactiveinvestors.com.au/companies/news/919118/maxcyte-gold-standard-technology-draws-crispr-pioneer-caribou-919118.html MaxCyte agrees clinical and commercial deal with US t-cell therapy expert https://www.proactiveinvestors.com.au/companies/news/919035/maxcyte-agrees-clinical-and-commercial-deal-with-us-t-cell-therapy-expert-919035.html Thu, 07 May 2020 06:21:00 +1000 https://www.proactiveinvestors.com.au/companies/news/919035/maxcyte-agrees-clinical-and-commercial-deal-with-us-t-cell-therapy-expert-919035.html MaxCyte prepares for "new and exciting" growth chapter - and NASDAQ float - following £25mln fundraiser https://www.proactiveinvestors.com.au/companies/news/918600/maxcyte-prepares-for--new-and-exciting--growth-chapter---and-nasdaq-float---following-25mln-fundraiser-918600.html Fri, 01 May 2020 06:27:00 +1000 https://www.proactiveinvestors.com.au/companies/news/918600/maxcyte-prepares-for--new-and-exciting--growth-chapter---and-nasdaq-float---following-25mln-fundraiser-918600.html Maxcyte reports 30% revenue growth as key programmes advance through clinical studies https://www.proactiveinvestors.com.au/companies/news/918319/maxcyte-reports-30-revenue-growth-as-key-programmes-advance-through-clinical-studies-918319.html Tue, 28 Apr 2020 13:19:00 +1000 https://www.proactiveinvestors.com.au/companies/news/918319/maxcyte-reports-30-revenue-growth-as-key-programmes-advance-through-clinical-studies-918319.html MaxCyte: Milestones a key contributor to 30% top line growth https://www.proactiveinvestors.com.au/companies/news/918273/maxcyte-milestones-a-key-contributor-to-30-top-line-growth-918273.html Tue, 28 Apr 2020 09:47:00 +1000 https://www.proactiveinvestors.com.au/companies/news/918273/maxcyte-milestones-a-key-contributor-to-30-top-line-growth-918273.html MaxCyte confident after strong year; hails long-term momentum of the business https://www.proactiveinvestors.com.au/companies/news/917702/maxcyte-confident-after-strong-year-hails-long-term-momentum-of-the-business-917702.html Tue, 21 Apr 2020 06:45:00 +1000 https://www.proactiveinvestors.com.au/companies/news/917702/maxcyte-confident-after-strong-year-hails-long-term-momentum-of-the-business-917702.html MaxCyte still expecting growth in the life sciences business this year https://www.proactiveinvestors.com.au/companies/news/916995/maxcyte-still-expecting-growth-in-the-life-sciences-business-this-year-916995.html Thu, 09 Apr 2020 06:40:00 +1000 https://www.proactiveinvestors.com.au/companies/news/916995/maxcyte-still-expecting-growth-in-the-life-sciences-business-this-year-916995.html MaxCyte: Allogene deal is validation for new CAR-T wave https://www.proactiveinvestors.com.au/companies/news/915907/maxcyte-allogene-deal-is-validation-for-new-car-t-wave-915907.html Thu, 26 Mar 2020 15:16:00 +1100 https://www.proactiveinvestors.com.au/companies/news/915907/maxcyte-allogene-deal-is-validation-for-new-car-t-wave-915907.html Maxcyte deal with Allogene Therapeutics 'a clear endorsement' of its technology https://www.proactiveinvestors.com.au/companies/news/915903/maxcyte-deal-with-allogene-therapeutics--a-clear-endorsement--of-its-technology-915903.html Thu, 26 Mar 2020 10:21:00 +1100 https://www.proactiveinvestors.com.au/companies/news/915903/maxcyte-deal-with-allogene-therapeutics--a-clear-endorsement--of-its-technology-915903.html Proactive news snapshot: MaxCyte, Learning Technologies, Minds + Machines, Tekcapital … https://www.proactiveinvestors.com.au/companies/news/915636/proactive-news-snapshot-maxcyte-learning-technologies-minds--machines-tekcapital--915636.html Tue, 24 Mar 2020 15:30:00 +1100 https://www.proactiveinvestors.com.au/companies/news/915636/proactive-news-snapshot-maxcyte-learning-technologies-minds--machines-tekcapital--915636.html